ACADIA Pharmaceuticals Inc. Financials

Market Capitalization $3.11 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	23.94
Forward PE	22.77
Price to Sales TTM	$3.34
Price to Book MRQ	$5.38
Enterprise to Revenue	2.79
Enterprise to EBITDA	20.80

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	13.83%
Operating Margin	12.64%
Return on Assets TTM	8.72%
Return on Equity TTM	27.36%

Income Statement

Revenue TTM	$929,235,968
Revenue per Share TTM	$5.62
Quarterly Revenue Growth	18.30%
Gross Profit TTM	$582,048,000
EBITDA	$124,541,000
Net Income to Common TTM	$128,506,000
Diluted EPS TTM	$0.78
Quarterly Earnings Growth YoY	18.28%

Balance Sheet

Total Cash MRQ	$565,329,984
Total Cash per Share MRQ	$3.40
Total Debt MRQ	$
Total Debt to Equity MRQ	8.55
Current Ratio MRQ	2.29
Book Value per Share MRQ	$3.47

Cash Flow

Operating Cash Flow TTM	$202,727,008
Levered Free Cash Flow TTM	$221,724,880

ACAD Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	166,392,000
Float Shares	108,970,049
Avg 10 Volume	1,993,780
Avg 30 Volume	None
Shares Short	10,718,622
Short Ratio	4.94
Short % of Shares	8.70%
% Held by Insiders	0.55%
% Held by Institutions	98.25%

Stock Price Summary

Beta	0.38
Fifty Two Week Low	$14.15
Fifty Two Week High	$27.94
Fifty Two Week Change	-47.51%
Day 50 MA	$17.31
Day 200 MA	$16.38

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date